Trial Profile
A multi-centre, randomized, double blind, placebo-controlled, parallel group study to investigate efficacy and safety of ONO-2506PO compared to placebo, in the presence of riluzole, to patients diagnosed with amyotrophic lateral sclerosis (ALS), who have had onset of muscle weakness within 14 months of randomization.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Arundic acid (Primary) ; Riluzole
- Indications Amyotrophic lateral sclerosis
- Focus Therapeutic Use
- Sponsors Ono Pharmaceutical
- 11 Dec 2008 Actual trial completion date identified as December 2008 from ClinicalTrials.gov.
- 11 Dec 2008 Actual trial completion date identified as December 2008 from ClinicalTrials.gov.
- 11 Dec 2008 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov.